Results 121 to 129 of about 4,657 (129)

Divisions Over the Regulation of Lecanemab

Lancet, The
Bart De Strooper, John Anthony Hardy
exaly  

Initial Experience With Lecanemab and Lessons Learned in 71 Patients in a Regional Medical Center

journal of prevention of Alzheimer's disease, The
C B Shields
exaly  

Characteristics of Adverse Events and Clinical Risks of Lecanemab Based on FAERS Data

Journal of Affective Disorders
Haohao Zhu, Rongrong Lu, Zhiqiang Du
exaly  

[125I]IPC-Lecanemab: Synthesis and Evaluation of Aβ-Plaque-Binding Antibody and Comparison With Small-Molecule [18F]Flotaza and [125I]IBETA in Postmortem Human Alzheimer’s Disease

Neurology International
Jogeshwar Mukherjee, Christopher Liang, Noresa L Gonzaga   +2 more
exaly  

Amyloid-Related Imaging Abnormalities in a Woman With Apolipoprotein E ε4 Homozygotes Treated With Lecanemab for Alzheimer's Disease

Clinical and Experimental Neuroimmunology
Kenjiro Ono, Moeko Noguchi-Shinohara
exaly  

How Will the Emergence of Lecanemab Change Dementia Treatment?

Geriatrics and Gerontology International
Atsushi Iwata
exaly  

Safety and Effectiveness of the Anti-Amyloid Monoclonal Antibody (mAb) Drug Lecanemab for Early Alzheimer's Disease: The Pharmacovigilance Perspective

British Journal of Clinical Pharmacology
Amy Bobbins, Elizabeth Lynn, Saad Shakir
exaly  

Divisions Over Lecanemab: Keeping an Open Mind

Lancet, The
exaly  

Re-Evaluation of the Efficacy and Safety of Anti-Aβ Monoclonal Antibodies (Lecanemab/Donanemab) in the Treatment of Early Alzheimer’s Disease

Frontiers in Pharmacology
exaly